Your browser does not support JavaScript!

Home  |   中文版  |  

Home > About NRICM > Director
Director

 

Jih-Hwa Guh

Guh, Jih-Hwa

Tel: +886-2-28201999 ext. 3101 or 886-2-28267179

Fax: +886-2-28230488 or 886-2-28225044

Email: jhguh@nricm.edu.tw

 

Current Position

Director, National Research Institute of Chinese Medicine, Ministry of Health and Welfare

 

Education

Ph.D. Pharmacology, National Taiwan University, 1992-1996
M.S. Pharmacology, National Taiwan University, 1990-1992
B.S. Pharmacy, National Taiwan University, 1986-1990

 

Experiences

2013/Aug - 2016/Jan Dean, School of Pharmacy, National Taiwan University
2011/Aug - 2013/Jul Director, School of Pharmacy, National Taiwan University
2010/Aug Professor, School of Pharmacy, National Taiwan University
2008/Jul - 2009/Jul Visiting Associate Professor, the Ohio State University
2004/Aug - 2010/Jul Associate Professor, School of Pharmacy, National Taiwan University
2000/Feb - 2004/Jul Assistant Professor, School of Pharmacy, National Taiwan University

Specialty

Pharmacology, Development of anticancer drugs

 

Research Description

We focus the research interests on the development of anticancer agents.

  1. Pharmacological evaluation of anticancer activity of chemically synthetic compounds and natural products.

  2.  Mechanism study of anticancer agents.

 

Publications

NCBI PubMed :  Jih-Hwa Guh (Please click!!)

  1. Hsu JL, Liu FL, Hsu LC, Chang HS, Leu WJ, Yu CC, Chang WL, Chen IS, Kung FL, Guh JH*. Epi-reevesioside F inhibits Na+/K+-ATPase, causing cytosolic acidification, Bak activation and apoptosis in glioblastoma. Oncotarget. 2015; 15:24032-24046.

  2. Chang WL, Hsu LC, Leu WJ, Chen CS, Guh JH*. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. Oncotarget. 2015; 24:39806-39820.

  3. Chang WL, Yu CC, Chen CS, Guh JH*. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry. Biochem Pharmacol. 2015;94:12-21.

  4. Ho CH, Hsu JL, Liu SP, Hsu LC, Chang WL, Chao CC, Guh JH*. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway. Prostate 2015;75:1454-1466.

  5. Kudryavtsev KV, Yu CC, Ivantcova PM, Polshakov VI, Churakov AV, Bräse S, Zefirov NS, Guh JH*. Structural studies and anticancer activity of a novel class of β-peptides. Chem Asian J. 2015;10:383-389.